报价延迟最少15分钟:2025/09/15 09:03 EDT
盘前时段
|
||||
|
7.2 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.97/0.62
|
|
企业价值
593.35M
|
| 资产负债 |
|
每股账面净值
-0.29
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
266.27M
|
|
每股收益
2.86
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/15 09:03 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada. |
